⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ONC News
BeOne Medicines Ltd. American Depositary Shares
L'FDA statunitense concede la verifica prioritaria a sonrotoclax per il trattamento del linfoma a cellule mantellari recidivante o refrattario
businesswire.com
ONC
Die US-amerikanische Arzneimittelbehörde FDA erteilt Sonrotoclax den Status der vorrangigen Prüfung für die Behandlung von rezidiviertem oder refraktärem Mantelzelllymphom
businesswire.com
ONC
美國FDA向sonrotoclax頒發用於治療復發或難治性套細胞淋巴瘤的優先審評資格
businesswire.com
ONC
米国FDA、再発・難治性マントル細胞リンパ腫の治療薬「ソンロトクラックス」に優先審査を付与
businesswire.com
ONC
U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
businesswire.com
ONC
BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025
businesswire.com
ONC
Positive Phase 3 Results Support ZIIHERA ® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA ® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
businesswire.com
ONC